Rapid Increase in Topical Diclofenac Use for Chronic Pain, 2011-2020.
文献摘要
Objectives To examine national prescribing patterns for topical diclofenac among Medicare beneficiaries with chronic pain and explore drivers of recent utilization trends, including pharmaceutical marketing and clinical guidelines. Study design Retrospective analysis of 100% Medicare Parts A, B, and D administrative claims data (2011-2020) linked with CMS Open Payments data (2013-2020) and a review of clinical literature. Methods We identified continuously enrolled beneficiaries with documented chronic pain episodes and calculated the proportion of these episodes involving topical diclofenac prescriptions. We compared these utilization trends with the timing of pharmaceutical marketing payments to prescribers, the usage of other nonopioid substitutes, and the publication dates of relevant clinical practice guidelines and systematic reviews. Results The share of chronic pain episodes treated with topical diclofenac grew sharply from 0.4% in 2015 to 6.8% in 2019. This increase of 6.4 percentage points (a 1620% relative increase) outpaced that of most other nonopioid substitutes, although gabapentinoids also saw substantial growth. Notably, this surge occurred in the absence of new, distinct clinical guidelines supporting its use and despite the near-cessation of pharmaceutical marketing payments for topical diclofenac by 2017; it did occur after the publication of the 2016 CDC opioid prescribing guideline. Conclusions The rapid rise of topical diclofenac usage likely did not directly follow marketing efforts or new efficacy data. Instead, it may reflect therapeutic substitution resulting from national efforts to curb opioid prescribing.